Status:

RECRUITING

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

Lead Sponsor:

Sanofi

Conditions:

Atopic Dermatitis

Eligibility:

All Genders

6+ years

Brief Summary

This is a Prospective, non-interventional (NIS) observational study in patients (≥6 years) with atopic dermatitis (AD) receiving dupilumab for the prospective evaluation of signs and symptoms, quality...

Eligibility Criteria

Inclusion

  • \- Patients are at least 6 years of age at the baseline visit. - Initial treatment with dupilumab was initiated in adults and adolescents 12 years of age and older with moderate to severe AD, or in children 6 to 11 years of age with severe AD according to the Summary of Product Characteristics. - Patients or their guardians are able to understand and complete the study-related questionnaires. - Signing a written informed consent form by the patients before the initiation of documentation within the framework of this NIS or informed consent of parents/guardian, if applicable.

Exclusion

  • \- Patients who have a contraindication for dupilumab based on the current Summary of Product Characteristics. - Patients who have already been treated with dupilumab for more than 7 days. - Any acute or chronic diseases, which, in the opinion of the attending physician, would impair the patient's ability to complete questionnaires or participate in this study or could affect the interpretation of the results. - Participation in an ongoing interventional or observational study, which, in the opinion of the attending physician, could affect the assessment of the current study. "The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."

Key Trial Info

Start Date :

March 7 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 8 2028

Estimated Enrollment :

900 Patients enrolled

Trial Details

Trial ID

NCT06039241

Start Date

March 7 2023

End Date

March 8 2028

Last Update

July 3 2025

Active Locations (55)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (55 locations)

1

Investigational Site Number: 061

Aachen, Germany, 52064

2

Investigational Site Number: 092

Ahaus, Germany, 48683

3

Investigational Site Number: 066

Andernach, Germany, 56626

4

Investigational Site Number: 002

Berlin, Germany, 10117

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis | DecenTrialz